Skip to main content
SpringerLink
Log in

Non-cosmetic Botulinum Toxin Treatments in the Head and Neck

  • Chapter
  • First Online:
Neurolaryngology

Abstract

Treatment of dystonias in the head and neck can be challenging for even the most experienced otolaryngologist. Available oral therapeutic options often fail to provide improvement in many patients and oftentimes come with intolerable systemic side effects that limit their use. With the introduction of botulinum toxin (BTX) to the treatment armamentarium for patients with dystonias, patients would have the chance for treatment by targeting only focal areas. With the use of BTX, treating physicians can focus treatment to only areas affected by the dystonia. This greatly minimizes the occurrence of systemic side effects. In this chapter, we will present a review of the history of the medical applications of BTX and discuss its role in the treatment of various dystonias of the head and neck.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 149.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol. 2000;43(2pt1):249–59.

    Article  CAS  PubMed  Google Scholar 

  2. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–9.

    Article  CAS  PubMed  Google Scholar 

  3. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans am Ophthalmol Society. 1981;79:734–70.

    CAS  Google Scholar 

  4. Scott AB, Kennedy RA, Stubbs HA. Botulinum a toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103:347–50.

    Article  CAS  PubMed  Google Scholar 

  5. Dutton JJ, Buckley EG. Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology. 1988;95:1529–34.

    Article  CAS  PubMed  Google Scholar 

  6. Savino PJ, Sergott RC, Bosley TM, Schatz NJ. Hemifacial spasm treated with botulinum A toxin injection. Arch Ophthalmol. 1985;103:1305–6.

    Article  CAS  PubMed  Google Scholar 

  7. Shon CC. Clostridium botulinum neurotoxins, their structures and modes of action. In: Watson ED, editor. Natural toxicants in foods. Chichester: Ellis Harwood, Ltd.; 1986. p. 11–57.

    Google Scholar 

  8. Coffield JA, Bakry N, Zhang RD, Carlson J, Gomella LG, Simpson LL. In vitro characterization of botulinum toxin types A, C, and D action on human tissues: combined electrophysiologic, pharmacologic, and molecular biologic approaches. J Pharmacol Exp Ther. 1997;280:1489–98.

    CAS  PubMed  Google Scholar 

  9. Binz T, Rummel A. Cell entry strategy of clostridial neurotoxins. J Neurochem. 2009;109:1584–95.

    Article  CAS  PubMed  Google Scholar 

  10. Alderson K, Holds JB, Anderson RL. Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology. 1991;41:1800–5.

    Article  CAS  PubMed  Google Scholar 

  11. Dressler D, Saberi AF. Botulinum toxin: mechanisms of action. E Neurol. 2005;53:3–9.

    Article  CAS  Google Scholar 

  12. McMahon SB, Bennett DLH, Bevan S. Inflammatory mediators and modulators of pain. In: McMahon SB, Koltzenberg M, editors. Wall and Melzack’s textbook of pain. 5th ed. Philadelphia, PA: Churchill Livingstone; 2005.

    Google Scholar 

  13. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60(7):1186–8.

    Article  CAS  PubMed  Google Scholar 

  14. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety and immunogenicity. Mov Disord. 1997;20:592–7.

    Article  Google Scholar 

  15. Kim EJ, Ramirez AL, Reeck JB, et al. The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines. Plast Reconstr Surg. 2003;112:88S–93S.

    Article  PubMed  Google Scholar 

  16. Li M, Goldberger BA, Carolyn H. Fatal case of Botox® -related anaphylaxis? J Forensic Sci. 2005;50:169–72.

    PubMed  Google Scholar 

  17. LeWitt PA, Trosch RM. Idiosyncratic adverse reactions to intramuscular botulinum toxin type a injection. Mov Disord. 1997;12:1064–7.

    Article  CAS  PubMed  Google Scholar 

  18. Ahbib S, Lachapelle JM, Marot L. Sarcoidal granulomas following injections of boltulic toxin a (Botox®) for corrections of wrinkles. Ann Dermatol Venereol. 2006;133:43–5. (in French)

    Article  CAS  PubMed  Google Scholar 

  19. Nettar K, Maas C. Neuromodulators: available agents, physiology and anatomy. Facial Plast Surg. 2011;27(6):517–22.

    Article  CAS  PubMed  Google Scholar 

  20. Carruthers J, Carruthers A. The evolution of botulinum neurotoxin type a for cosmetic applications. J Cosmetic Laser Ther. 2007;9(3):186–92.

    Article  Google Scholar 

  21. Matarasso A, Shafer D. Botulinum neurotoxin type A-ABO (Dysport®): clinical indications and practice guide. Aesthet Surg J. 2009;29(6 Suppl):S72–9.

    Article  PubMed  Google Scholar 

  22. Kane MA. The effects of botulinum toxin injections on the nasolabial fold. Plast Reconstr Surg. 2003;112(Suppl 5):66S–72S. (discussion 73S–74S)

    Article  PubMed  Google Scholar 

  23. Kranz G, Haubenberger D, Voller B, et al. Respective potencies of Botox® and Dysport® in a human skin model: a randomized, double blind study. Mov Disord. 2009;24:231–6.

    Article  PubMed  Google Scholar 

  24. Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs. 2007;67:669–83.

    Article  CAS  PubMed  Google Scholar 

  25. Rieder CR, Schestatsky P, Socal MP, et al. A double-blind randomized, crossover study of Prosigne® vs. Botox ® in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007;30(1):39–42.

    Article  PubMed  Google Scholar 

  26. Hunte T, Clarke K. Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test. J Am Acad Dermatol. 2008;58(3):517–8.

    Article  Google Scholar 

  27. Spencer JM, Gordon M, Goldberg DJ. Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis. J Cosmet Laser Ther. 2002;4:19–23.

    Article  PubMed  Google Scholar 

  28. Jacob CI. Botulinum neurotoxin type-B—a rapid wrinkle reducer. Semin Cutan Med Surg. 2007;22(2):131–5.

    Article  Google Scholar 

  29. Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg. 1998;24:1179–80.

    CAS  PubMed  Google Scholar 

  30. Kwiat DM, Bersani TA, Bersani A. Increased patient comfort utilizing botulinum toxin A reconstituted with preserved versus nonpreserved saline. Ophthal Plast Reconstr Surg. 2004;20:186–9.

    Article  PubMed  Google Scholar 

  31. Sarifakioglu N, Sarifakioglu E. Evaluating effects of preservative-containing saline solution on pain perception during botulinum toxin type A injections at different locations: a prospective, single-blinded, randomized controlled trial. Aesth Plast Surg. 2005;29:113–5.

    Article  Google Scholar 

  32. U.S. Food and Drug Administration. Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox®), AbobotulinumtoxinA (marketed as Dysport®) and RimabotulinumtoxinB (marketed as Myobloc®). http://www.fda.gov/Drugs/Drugsafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm174949.htm. Accessed Nov 2014.

  33. Carruthers J, Carruthers A. The evolution of botulinum neurotoxin type A for cosmetic applications. J Cosmet Laser Ther. 2007;9(3):186–92.

    Article  PubMed  Google Scholar 

  34. Gassner HG, Sherris DA. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type a injections: a randomized controlled study. Mayo Clin Proc. 2000;75:701–4.

    Article  CAS  PubMed  Google Scholar 

  35. Haubner F. Simultaneous injection of lidocaine improves predictability of effect of botulinum toxin. Laryngorhinootologie. 2009;88:764.

    Article  CAS  PubMed  Google Scholar 

  36. Kenner JR. Hyaluronic acid filler and botulinum neurotoxin delivered simultaneously in the same syringe for effective and convenient combination aesthetic rejuvenation therapy. J Drug Dermatol. 2010;9:1135–8.

    Google Scholar 

  37. Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type a reconstituted in lidocaine or in normal saline: a randomized side-by-side, double-blind study. Br J Dermatol. 2007;156:986–9.

    Article  CAS  PubMed  Google Scholar 

  38. Moore P, Naumann M. General and clinical aspect of treatment with botulinum toxin. In: Moore P, Naumann M, eds. Handbook of botulinum toxin treatment, 2nd ed., 3. Massachusetts: Blackwell Science; 2003:41.

    Google Scholar 

  39. Trindade De Almeida AR, Secco LC, Carruthers A. Handling botulinum toxins: an updated literature review. Dermatol Surg. 2011;37(11):1553–65.

    Article  CAS  PubMed  Google Scholar 

  40. Barrow EM, Rosen CA, Hapner ER, Smith S, Hatcher JL, Simpson B, Johns MM III. Safety and efficacy of multiuse botulinum toxin vials for intralaryngeal injection. Laryngoscope. 2015;125(5):1149–54.

    Article  CAS  PubMed  Google Scholar 

  41. Cosmetic B. Botox (package insert). Irvine, CA: Allergan, Inc.; 2000.

    Google Scholar 

  42. Gartlan MG, Hoffman HG. Crystalline preparation of botulinum toxin type A (Botox): degradation of potency with storage. Otolaryngol Head Neck Surg. 1993;108(2):135–40.

    Article  CAS  PubMed  Google Scholar 

  43. Greene P. Potency of frozen/thawed botulinum toxin type A in the treatment of torsional dystonia. Surg. 1993;109(5):968–9.

    CAS  Google Scholar 

  44. Sloop RR, Cole BA, Escutin RO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology. 1997;48(1):249–53.

    Article  CAS  PubMed  Google Scholar 

  45. Thomas JP, Slupinskiene N. Frozen versus fresh reconstituted Botox for laryngeal dystonia. Otolaryngol Head Neck Surg. 2006;135(2):204–8.

    Article  PubMed  Google Scholar 

  46. Yang GC, Chiu RJ, Gillman GS. Questioning the need to use botox within 4 hours of reconstitution. Arch Facial Plast Surg. 2008;10(4):273–9.

    Article  PubMed  Google Scholar 

  47. Blitzer A, Crumley RL, Dailey SH, et al. Recommendations of the neurolaryngology study group on laryngeal electromyography. Otolaryngol Head Neck Surg. 2009;140(6):782–93. doi:10.1016/j.otohns.2009.01.026.

    Article  PubMed  Google Scholar 

  48. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-years experience in more than 900 patients. Laryngoscope. 1998;108:1435–41.

    Article  CAS  PubMed  Google Scholar 

  49. Nygaard TG, Trugman JM, de Yebenes JG, Fahn S. Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology. 1990;40:66–9.

    Article  CAS  PubMed  Google Scholar 

  50. Pahwa R, Lyons KE. Essential tremor: differential diagnosis and current therapy. Am J Med. 2003;115:134–42.

    Article  PubMed  Google Scholar 

  51. Bové M, Daamen N, Rosen C, Wang CC, Sulica L, Gartner-Schmidt J. Development and validation of the vocal tremor scoring system. Laryngoscope. 2006;116(9):1662–7.

    Article  PubMed  Google Scholar 

  52. Gurey LE, Sinclair CF, Blitzer A. A new paradigm for the management of essential vocal tremor with botulinum toxin. Laryngoscope. 2013;123(10):2497–501. doi:10.1002/lary.24073.

    CAS  PubMed  Google Scholar 

  53. Simpson CB, Rosen CA. Botulinum toxin injection of the larynx. In: Simpson CB, Rosen CA, editors. Operative techniques in laryngology. Heidelberg: Springer Verlag; 2008. p. 221–7.

    Google Scholar 

  54. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology. 1986;36:160–4.

    Article  CAS  PubMed  Google Scholar 

  55. Fahn S. Generalized dystonia: concept and treatment. Clin Neuropharmacol. 1986;9:S37–48.

    Article  PubMed  Google Scholar 

  56. Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol. 1992;15:276–88.

    Article  CAS  PubMed  Google Scholar 

  57. Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol. 1983;13:402–11.

    Article  CAS  PubMed  Google Scholar 

  58. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982;11:41–7.

    Article  CAS  PubMed  Google Scholar 

  59. Rodriguez RL, Fernandez HH, Haq I, Okun MS. Pearls in patient selection for deep brain stimulation. Neurologist. 2007;13:253–60.

    Article  PubMed  Google Scholar 

  60. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ III. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov. Disord. 1988;3(3):188–94.

    Article  CAS  Google Scholar 

  61. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439–46.

    Article  CAS  PubMed  Google Scholar 

  62. Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology. 2000;55(12 suppl 5):S15–21.

    CAS  PubMed  Google Scholar 

  63. Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin naïve patients with cervical dystonia: randomized, double blind, noninferiority trial. Mov Disord. 2008;23(4):510–7.

    Article  PubMed  Google Scholar 

  64. Neumann A, Rosenberger D, Vorsprach O, Dazert S. The incidence of Frey syndrome following parotidectomy: results of a survey and follow up. HNO. 2011;59:173–8.

    Article  CAS  PubMed  Google Scholar 

  65. Beerens AG, Snow GB. Botulinum toxin a in the treatment of patients with Frey syndrome. Br J Surg. 2002;89:116–9.

    Article  CAS  PubMed  Google Scholar 

  66. Cantarella G, Berlusconi A, Mele V, Cogiamanian F, Barbieri S. Treatment of Frey’s syndrome with botulinum toxin type B. Otolaryng Head Neck Surg. 2010;143:214–8.

    Article  Google Scholar 

  67. de Bree R, Duyndam JE, Kuik DJ, Leemans CR. Repeated botulinum toxin type a injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg. 2009;135:287–90.

    Article  PubMed  Google Scholar 

  68. Drobik C, Laskawi R. Frey’s syndrome: treatment with botulinum toxin. Acta Otolaryngol. 1995;115:459–61.

    Article  CAS  PubMed  Google Scholar 

  69. Pomprasit M, Chintrakarn C. Treatment of Frey’s syndrome with botulinum toxin. J Med Assoc Thail. 2007;90:2397–402.

    Google Scholar 

  70. Haubrich WS. The first-bite syndrome. Henry Ford Hospit Med J. 1986;34:275–8.

    CAS  Google Scholar 

  71. Chiu AG, Cohen JI, Burningham AR, Andersen PE, Davidson VJ. First bite syndrome: a complication of surgery involving the parapharyngeal space. Head Neck. 2002;24:996–9.

    Article  PubMed  Google Scholar 

  72. Netterville JL, Jackson CG, Miller FR, Wanamaker JR, Glasscock ME. Vagal paraganglioma: a review of 46 patients treated during a 20-year period. Arch Otolaryngol Head Neck Surg. 1998;124:1133–40.

    Article  CAS  PubMed  Google Scholar 

  73. Lee BJ, Lee JC, Lee YO, Wang SG, Kim HJ. Novel treatment of first bite syndrome using botulinum toxin type a. Head Neck. 2008;31(8):989–93. doi:10.1002/hed.21054.

    Article  Google Scholar 

  74. Chao SS, Graha SM, Hoffman HT. Management of pharyngoesophageal spasm with botox. Otolaryngol Clin N Am. 2004;37:559–66.

    Article  Google Scholar 

  75. Blitzer A, Komisar A, Baredes S, Brin MF, Stewart C. Voice failure after tracheoesophageal puncture: management with botulinum toxin. Otolaryng Head Neck Surg. 1995;113:668–70.

    Article  CAS  Google Scholar 

  76. Bartolomei L, Zambito Marsala S, Pighi GP, et al. Botulinum toxin type a: an effective treatment to restore phonation in laryngectomized patients unable to voice. Neurol Sci. 2011;32:443–7.

    Article  PubMed  Google Scholar 

  77. Lewis JS, Bishop-Leone JK, Forman AD, Diaz EM Jr. Further experience with botox injection for tracheoesophageal speech failure. Head Neck. 2001;23:456–60.

    Article  Google Scholar 

  78. Meleca RJ, Dworkin JP, Zormeier MM, Simpson ML, Shibuya T, Mathog RH. Videostroboscopy of the pharyngoesophageal segment in laryngectomy patients treated with botulinum toxin. Otolaryngol Head Neck Surg. 2000;123:38–43.

    Article  CAS  PubMed  Google Scholar 

  79. Zormier MM, Meleca RJ, Simpson ML, et al. Botulinum toxin injection to improve tracheoesophageal speech after total laryngectomy. Otolaryngol Head Neck Surg. 1999;120:314–9.

    Article  Google Scholar 

  80. Hamaker C, Blom ED. Botulinum neurotoxin for pharyngeal constrictor muscle spasm in tracheoesophageal voice restoration. Laryngoscope. 2003;113:1479–82.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology, University of Pittsburgh Voice Center, Building D.Suite 2100, 1400 Locust Street, Pittsburgh, PA, 15219, USA

    Lyndsay L. Madden & Clark A. Rosen

Authors
  1. Lyndsay L. Madden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clark A. Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clark A. Rosen .

Editor information

Editors and Affiliations

  1. Department of Otorhinolaryngology/Head and Neck Surgery, Clinical Centre Stuttgart, Stuttgart, Germany

    Christian Sittel

  2. Department of Otorhinolaryngology and Institute of Phoniatry and Pedaudiology, Jena University Hospital, Jena, Germany

    Orlando Guntinas-Lichius

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Madden, L.L., Rosen, C.A. (2018). Non-cosmetic Botulinum Toxin Treatments in the Head and Neck. In: Sittel, C., Guntinas-Lichius, O. (eds) Neurolaryngology. Springer, Cham. https://doi.org/10.1007/978-3-319-61724-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-61724-4_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-61722-0

  • Online ISBN: 978-3-319-61724-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation